Comparison of some clinical data from the PROTECT AF versus new oral anticoagulant trials *
| PROTECT AF55 LAA closure | PROTECT AF55 warfarin | Dabigatran14 (RELY) | Rivaroxaban15 (ROCKET AF) | Apixaban16 (ARISTOTLE) | |
|---|---|---|---|---|---|
| Age, years | 71.7 | 72.7 | 71.5 | 73 | 70 |
| CHADS2 | 2.2 | 2.3 | 2.1 | 3.5 | 2.1 |
| CHADS2>2 (%) | 52.9 | 57.6 | 32.7 | 87 | 30.2 |
| Major or minor bleeding (%) | – | – | 16.4 | 14.9 | 18.1 |
| Major bleeding (%) | 3.5 | 4.1 | 3.1 | 3.6 | 2.1 |
| Stroke/systemic embolism (%) | 2.3 | 2.7 | 1.1 | 1.7 | 1.3 |
| Treatment abandoned at >1 year (%) | – | 16–34 | 21 | 24 | – |
*Adapted from López-Mínguez et al.72